PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Autophagy
/ drug effects
Cell Line, Tumor
Cell Movement
/ drug effects
Chloroquine
/ pharmacology
Cisplatin
/ pharmacology
Drug Resistance, Neoplasm
/ drug effects
Female
Gene Expression Regulation, Neoplastic
/ drug effects
HEK293 Cells
Humans
MAP Kinase Signaling System
/ genetics
MDS1 and EVI1 Complex Locus Protein
/ genetics
Macrolides
/ pharmacology
Middle Aged
Mitogen-Activated Protein Kinase Kinases
/ antagonists & inhibitors
Neoplasm Metastasis
Ovarian Neoplasms
/ genetics
Prognosis
Retrospective Studies
Signal Transduction
/ drug effects
TOR Serine-Threonine Kinases
/ genetics
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
18 02 2019
18 02 2019
Historique:
received:
26
10
2018
accepted:
01
02
2019
revised:
17
01
2019
entrez:
20
2
2019
pubmed:
20
2
2019
medline:
21
4
2020
Statut:
epublish
Résumé
High-grade serous ovarian carcinoma (HGSOC) is the most lethal type of gynecologic malignancy. Chemoresistance is the main reason for the poor prognosis of HGSOC. PDZ-binding kinase (PBK) promotes the malignant progression of various carcinomas. However, the roles and clinical significance of PBK in HGSOC remain unclear. Here, we reported that PBK was overexpressed in HGSOC tissues and cell lines. High PBK expression was associated with a poor prognosis, metastasis, and cisplatin resistance of HGSOC. Overexpression of PBK promoted autophagy and enhanced cisplatin resistance via the ERK/mTOR signaling pathway. Further study showed that inhibition of autophagy by chloroquine or bafilomycin A1 reversed PBK-induced cisplatin resistance. Overexpression of PBK decreased ovarian cancer responsiveness to cisplatin treatment through inducing autophagy in vivo. We also demonstrated that the PBK inhibitor OTS514 augmented the growth inhibition effect of cisplatin in vitro and in vivo. Moreover, ecotropic viral integration site-1 (EVI1) could regulate PBK expression through directly targeting the PBK promoter region. In conclusion, high PBK expression was correlated with a poor prognosis, metastasis, and cisplatin resistance through promoting autophagy in HGSOC. PBK might be a promising target for the early diagnosis and individual treatment of ovarian cancer.
Identifiants
pubmed: 30778048
doi: 10.1038/s41419-019-1415-6
pii: 10.1038/s41419-019-1415-6
pmc: PMC6379381
doi:
Substances chimiques
Antineoplastic Agents
0
MDS1 and EVI1 Complex Locus Protein
0
MECOM protein, human
0
Macrolides
0
Chloroquine
886U3H6UFF
bafilomycin A1
88899-55-2
MTOR protein, human
EC 2.7.1.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Mitogen-Activated Protein Kinase Kinases
EC 2.7.12.2
PDZ-binding kinase
EC 2.7.12.2
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
166Références
Trends Biochem Sci. 2011 Jun;36(6):320-8
pubmed: 21531565
J Cell Biol. 2005 May 9;169(3):425-34
pubmed: 15866887
Br J Cancer. 1996 Nov;74(10):1518-25
pubmed: 8932329
Nature. 2000 Nov 23;408(6811):488-92
pubmed: 11100732
Ann Oncol. 2017 Nov 1;28(suppl_8):viii13-viii15
pubmed: 29232469
Hum Pathol. 2015 Feb;46(2):217-24
pubmed: 25466965
Cell Death Dis. 2017 Mar 23;8(3):e2693
pubmed: 28333152
Int J Mol Sci. 2016 Jun 24;17(7):
pubmed: 27347940
Endocr Relat Cancer. 2018 May;25(5):R303-R318
pubmed: 29487129
Oncogene. 2010 Oct 7;29(40):5464-74
pubmed: 20622899
Oncotarget. 2016 Feb 9;7(6):6748-64
pubmed: 26745678
Cancer Res. 2006 Sep 15;66(18):9186-95
pubmed: 16982762
ACS Chem Biol. 2010 Nov 19;5(11):1035-43
pubmed: 20822188
Cancer Lett. 2011 Aug 28;307(2):141-8
pubmed: 21511395
Oncogene. 2007 May 24;26(24):3451-61
pubmed: 17160018
J Neurosci. 2005 Nov 16;25(46):10773-85
pubmed: 16291951
Oncogene. 2012 May 10;31(19):2389-400
pubmed: 21996732
Ann Oncol. 2017 Nov 1;28(suppl_8):viii1-viii7
pubmed: 29232467
Genes Dev. 2016 Sep 1;30(17):1913-30
pubmed: 27664235
Biochem Biophys Res Commun. 2017 Jun 24;488(2):247-252
pubmed: 28373071
Annu Rev Cell Dev Biol. 2011;27:107-32
pubmed: 21801009
Cell Death Dis. 2018 May 29;9(6):649
pubmed: 29844404
Cell Death Dis. 2018 Oct 24;9(11):1089
pubmed: 30356039
Nat Rev Mol Cell Biol. 2018 Jun;19(6):349-364
pubmed: 29618831
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
J Biol Chem. 2000 Jul 14;275(28):21525-31
pubmed: 10781613
Oncotarget. 2015 Jun 20;6(17):15594-609
pubmed: 25909225
Cancer Res. 2012 Jun 15;72(12):3060-8
pubmed: 22523035
Oncotarget. 2017 Jul 18;8(29):47195-47205
pubmed: 28525379
Autophagy. 2011 May;7(5):509-24
pubmed: 21325880
Oncotarget. 2015 Oct 20;6(32):33410-25
pubmed: 26450903
J Biol Chem. 2014 Jun 13;289(24):17163-73
pubmed: 24794870
Int J Cancer. 2018 Sep 15;143(6):1456-1469
pubmed: 29663364
Oncogene. 2019 Feb;38(7):1136-1150
pubmed: 30237440
Oncotarget. 2016 Apr 5;7(14):17652-64
pubmed: 26933922
Cancer Res. 2007 Apr 1;67(7):3074-84
pubmed: 17409414
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5167-72
pubmed: 10779557
Oncotarget. 2017 Dec 26;9(8):7782-7795
pubmed: 29487691
Sci Transl Med. 2014 Oct 22;6(259):259ra145
pubmed: 25338756
Br J Cancer. 2017 Jan 17;116(2):218-226
pubmed: 27898655
Gastroenterology. 2007 Jul;133(1):219-31
pubmed: 17631144
J Mol Biol. 2007 Jul 6;370(2):231-45
pubmed: 17512944
BMC Cancer. 2009 Oct 18;9:368
pubmed: 19835627
Int J Biol Macromol. 2015 Nov;81:615-23
pubmed: 26314905
Leuk Res. 2013 Apr;37(4):447-54
pubmed: 23237560
Carcinogenesis. 2018 Dec 31;39(12):1548-1559
pubmed: 30165468
Leuk Res. 2006 Apr;30(4):437-47
pubmed: 16171862
Nat Rev Cancer. 2012 Apr 26;12(6):401-10
pubmed: 22534666
Clin Cancer Res. 2016 Dec 15;22(24):6110-6117
pubmed: 27334838
J Biol Chem. 2012 Feb 3;287(6):4148-56
pubmed: 22157765
Cancer Lett. 2019 Mar 31;445:11-23
pubmed: 30590102
Mol Cancer. 2015 Jun 17;14:121
pubmed: 26081429
Oncotarget. 2016 May 3;7(18):26604-16
pubmed: 27049917
BMC Med Genomics. 2009 Jun 08;2:34
pubmed: 19505326
Br J Cancer. 2010 Jan 5;102(1):151-61
pubmed: 19935791